Occulo Holdings
Immunotherapy development for various diseases using proprietary technology
About Occulo Holdings
Occulo Holdings is a biotechnology group focused on developing immunotherapies for treating various diseases through its subsidiary companies, including OcculoBio, Stealth Biologics, and Lyticon. Founded in 2016 by Karl Griswold and Chris Bailey Kellogg, the company is based in Lebanon, New Hampshire, USA. The founders, Griswold (CEO) and Kellogg (CTO), lead the company's scientific and technological direction.
The company's proprietary technology integrates advanced computational models, protein design algorithms, and protein engineering methods. This platform is designed to develop a range of biotherapies such as antibodies, enzymes, and toxins by using immunoassays to guide the process. Occulo aims to create new treatments by leveraging its computational and protein engineering expertise.
The company has secured $12.8 million in funding from at least one institutional investor, the Dartmouth Regional Technology Center, to support its research and development activities. According to market analysis, Occulo operates in a competitive landscape but has ceased operations.
Source: Dealroom company dataNews
Open roles
Occulo Holdings in the Lebanon ecosystem
The Occulo Holdings office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Occulo Holdings on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Occulo Holdings on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

